Darifenacin

Chemical formula: C₂₈H₃₀N₂O₂  Molecular mass: 426.55 g/mol  PubChem compound: 444031

Therapeutic indications

Darifenacin is indicated for:

Overactive bladder syndrome

Population group: only adults (18 years old or older)

Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Darifenacin is contraindicated in the following cases:

Urinary retention

Retention of urine

Gastric retention

Gastric retention

Uncontrolled narrow-angle glaucoma

Angle-closure glaucoma

Myasthenia gravis

Myasthenia gravis

Severe ulcerative colitis

Severe chronic ulcerative colitis

Toxic megacolon

† Toxic megacolon

Potent CYP3A4 inhibitors

Strong CYP3A4 inhibitors

Severe hepatic impairment (Child Pugh C)

Hepatic failure stage IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2016: ENABLEX Extended-release tablet
Summary of Product Characteristics (SPC) 2020: EMSELEX Prolonged-release tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈